SEC Form 4Coverage since May 22, 2026
$ONC insider trading
Over the last 12 months, BeOne Medicines insiders reported no purchases and 32 sales totaling $215.7M across SEC Form 4 filings. 22% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $215.7M 32 events
- Events · 12m
- 32 Form 4 filings, grouped
- Insiders · 12m
- 11 distinct reporters
- 10b5-1 share
- 22% pre-arranged plans
Side
Price · $ONC · 12Mvia TradingView
Top insiders · 12m
OYLER JOHNChief Executive Officer9× · $210.7M
Lee Chan HenrySVP, General Counsel6× · $1.6M
Wang LaiPresident, Global Head of R&D4× · $1.2M
Wu XiaobinPresident and COO4× · $1.3M
Ball Titus B.Principal Accounting Officer2× · $80K
All insider trades
32 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Rosenberg AaronChief Financial Officer · O | ▼ Sale | 1,157 | $312.72 | $362K | -100% | — |
| Jul 30, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 1,044 | $323.69 | $338K | -100% | — |
| Jul 22, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 1,669 | $325 | $542K | -100% | plan |
| Jul 21, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 109,713 | $315.28 | $34.6M | -100% | plan · 14 tranches |
| Jul 17, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 64,628 | $312 | $20.2M | -100% | plan · 9 tranches |
| Jul 16, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 283,154 | $315.56 | $89.4M | -100% | plan · 17 tranches |
| Jul 14, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 145,861 | $305.95 | $44.6M | -100% | plan · 6 tranches |
| Jul 13, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 60,218 | $303.18 | $18.3M | -100% | plan · 15 tranches |
| Jul 8, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 664 | $302.46 | $201K | -100% | plan |
| Jun 23, 2026 | Wu XiaobinPresident and COO · O | ▼ Sale | 1,292 | $276.26 | $357K | -100% | — |
| Jun 23, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 3,410 | $273.78 | $934K | -100% | 3 tranches |
| Jun 23, 2026 | Wang LaiPresident, Global Head of R&D · O | ▼ Sale | 1,068 | $276.74 | $296K | -100% | — |
| Jun 16, 2026 | Wu XiaobinPresident and COO · O | ▼ Sale | 1,357 | $266.76 | $362K | -100% | — |
| Jun 16, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 3,693 | $265.55 | $981K | -100% | 3 tranches |
| Jun 16, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 590 | $265.98 | $157K | -100% | — |
| Jun 16, 2026 | Wang LaiPresident, Global Head of R&D · O | ▼ Sale | 1,169 | $265.39 | $310K | -100% | — |
| Jun 11, 2026 | Ball Titus B.Principal Accounting Officer · O | ▼ Sale | 169 | $257.2 | $43K | -100% | 2 tranches |
| Jun 11, 2026 | Wang LaiPresident, Global Head of R&D · O | ▼ Sale | 756 | $261 | $197K | -100% | — |
| Jun 11, 2026 | Rosenberg AaronChief Financial Officer · O | ▼ Sale | 631 | $257.74 | $163K | -100% | — |
| Jun 11, 2026 | Wu XiaobinPresident and COO · O | ▼ Sale | 626 | $261.2 | $164K | -100% | — |
| Jun 11, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 428 | $257.64 | $110K | -100% | — |
| Jun 11, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 1,949 | $257.24 | $501K | -100% | 4 tranches |
| Jun 8, 2026 | Ball Titus B.Principal Accounting Officer · O | ▼ Sale | 136 | $271.33 | $37K | -100% | 2 tranches |
| Jun 8, 2026 | Lee Chan HenrySVP, General Counsel · O | ▼ Sale | 871 | $270.42 | $236K | -100% | 2 tranches |
| Jun 8, 2026 | Wang LaiPresident, Global Head of R&D · O | ▼ Sale | 1,367 | $269.38 | $368K | -100% | 2 tranches |
| Jun 8, 2026 | Wu XiaobinPresident and COO · O | ▼ Sale | 1,484 | $269.37 | $400K | -100% | 2 tranches |
| Jun 8, 2026 | OYLER JOHNChief Executive Officer · O·D | ▼ Sale | 4,940 | $270.56 | $1.3M | -100% | 2 tranches |
| Jun 1, 2026 | Yi QingqingD | ▼ Sale | 235 | $279.13 | $66K | -100% | — |
| May 22, 2026 | Riva AlessandroD | ▼ Sale | 212 | $309.51 | $66K | -100% | — |
| May 22, 2026 | Dugan MargaretD | ▼ Sale | 212 | $309.6 | $66K | -100% | — |
| May 22, 2026 | Sanders Corazon (Corsee) D.D | ▼ Sale | 212 | $309.59 | $66K | -100% | — |
| May 22, 2026 | BAKER BROS. ADVISORS LPD | ▼ Sale | 2,743 | $23.85 | $65K | -1.9% | indirect |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ONC feed.